Next to Lead

Next to Lead

Big Pharma's Trust Gap? How Gilead Is Rewriting the Narrative | Next to Lead

30 min · 13 de abr de 2026
Portada del episodio Big Pharma's Trust Gap? How Gilead Is Rewriting the Narrative | Next to Lead

Descripción

Gilead Sciences moves at a pace rarely seen in pharma, delivering breakthrough COVID-19 antivirals and HIV preventatives in record time. Yet, in an industry facing a massive trust deficit, speed isn’t always enough.  In this episode of Next to Lead, Johanna Mercier, Gilead’s Chief Commercial & Corporate Affairs Officer, joins Fortune’s Leadership Editor Ruth Umoh to discuss how the company is rewriting its narrative and balancing its patients with its shareholders. 00:00 Intro 01:05 Mercier’s role at Gilead 03:05 Work-life balance and managing energy 05:10 Mercier’s biology and business background 06:02 Personal motivation and prioritizing patients 08:10 Balancing profits with patients 09:04 Public trust 11:03 Resilience following failure 13:02 Drug pricing agreements with the federal government 14:33 Growth engines for Gilead 15:24 Gilead’s billion-dollar acquisition strategy 17:24 Gilead’s COVID-19 and SARS pivot 18:07 Gilead’s AI strategy 21:34 Responsible AI use 22:10 AI-powered predictive analytics 23:07 Mercier’s leadership strategy 24:24 Ending HIV 25:30 Rapid-fire questions 30:45 Outro Learn more about your ad choices. Visit megaphone.fm/adchoices [https://megaphone.fm/adchoices]

Comentarios

0

Sé la primera persona en comentar

¡Regístrate ahora y únete a la comunidad de Next to Lead!

Prueba gratis

Empieza 7 días de prueba

$99 / mes después de la prueba. · Cancela cuando quieras.

  • Podcasts solo en Podimo
  • 20 horas de audiolibros al mes
  • Podcast gratuitos

Todos los episodios

18 episodios

episode How Carvana Survived a 99% Stock Collapse | Next to Lead artwork

How Carvana Survived a 99% Stock Collapse | Next to Lead

In late 2022, Carvana was flirting with bankruptcy after its stock collapsed 99% in just 16 months. Now, the online used-car retailer is staging a stunning comeback, pouring billions into acquisitions, infrastructure, AI, and its signature car vending machines.  In this episode of Next to Lead, Fortune’s C-suite and Leadership editor Ruth Umoh sits down with Carvana strategy chief Christina Keiser to discuss what it will take to sustain that momentum and how it came back from the brink. 00:00 Intro 01:05 What is Carvana 04:49 Carvana’s online shopping business model 06:32 Christina’s rise to the C-suite 08:20 Christina’s strategy role at Carvana 10:56 Carvana’s vision 11:51 Christina’s vision 12:34 Managing Carvana’s stock crash 16:37 Looking back at Carvana’s crisis 19:00 Staying focused in leadership 21:27 Carvana’s inventory strategy 23:04 Balancing rising interest rates 25:28 Carvana’s ADESA auction acquisition 28:55 Carvana’s car vending machines 31:30 Carvana’s AI strategy 33:47 Christina’s best leadership advice 34:13 Christina’s advice for recovering from a career mistake 34:37 Christina’s personal car and outro Learn more about your ad choices. Visit megaphone.fm/adchoices [https://megaphone.fm/adchoices]

27 de abr de 202634 min
episode Big Pharma's Trust Gap? How Gilead Is Rewriting the Narrative | Next to Lead artwork

Big Pharma's Trust Gap? How Gilead Is Rewriting the Narrative | Next to Lead

Gilead Sciences moves at a pace rarely seen in pharma, delivering breakthrough COVID-19 antivirals and HIV preventatives in record time. Yet, in an industry facing a massive trust deficit, speed isn’t always enough.  In this episode of Next to Lead, Johanna Mercier, Gilead’s Chief Commercial & Corporate Affairs Officer, joins Fortune’s Leadership Editor Ruth Umoh to discuss how the company is rewriting its narrative and balancing its patients with its shareholders. 00:00 Intro 01:05 Mercier’s role at Gilead 03:05 Work-life balance and managing energy 05:10 Mercier’s biology and business background 06:02 Personal motivation and prioritizing patients 08:10 Balancing profits with patients 09:04 Public trust 11:03 Resilience following failure 13:02 Drug pricing agreements with the federal government 14:33 Growth engines for Gilead 15:24 Gilead’s billion-dollar acquisition strategy 17:24 Gilead’s COVID-19 and SARS pivot 18:07 Gilead’s AI strategy 21:34 Responsible AI use 22:10 AI-powered predictive analytics 23:07 Mercier’s leadership strategy 24:24 Ending HIV 25:30 Rapid-fire questions 30:45 Outro Learn more about your ad choices. Visit megaphone.fm/adchoices [https://megaphone.fm/adchoices]

13 de abr de 202630 min